The earlier cancer is found, the higher the chance everyone wins: likely better outcomes for those finding it and greater peace of mind for those without it. Offering GalleriTM, a multi-cancer early detection test, was found to encourage employees to join, stay, and understand they’re part of a workplace that truly cares.1
The Galleri test is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older.
With the Galleri test, employees could receive the benefits of early detection of multiple cancers through a simple blood draw.
50+ cancer types detected
including cancers employees aren’t routinely screened for today9,10
0.5% false-positive rate
to help minimize unnecessary medical procedures9
in predicting the location of the cancer, directing diagnostic workup9
Important safety information
The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests. Results should be interpreted by a healthcare provider. A “Cancer Signal Not Detected” result does not rule out cancer. A “Cancer Signal Detected” result requires confirmatory diagnostic evaluation (e.g. imaging), and if cancer is not confirmed, it may not be present, may not be detectable by diagnostic follow-up testing or may be located in a different part of the body. False-positive and false-negative test results do occur. Rx only.
Laboratory / test information
The GRAIL laboratory is CLIA-certified and CAP-accredited. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by FDA. The GRAIL laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is for clinical purposes.